Adient's 'Attractive Valuation' Limits Downside as Shares Trade Near Cyclical Lows, UBS Says

MT Newswires Live
Jan 15

Adient (ADNT) has an "attractive valuation" with the stock trading near cyclical lows at about four times next-12-month enterprise value-to-earnings before interest, taxes, depreciation and amortization, limiting downside risk, UBS Securities said in a report Wednesday.

UBS has upgraded the automotive seating maker to buy from neutral, and raised its price target to $30 from $22, citing improving cash flow prospects, the report said, adding that the investment bank expects Adient to generate as much as $300 million in annual free cash flow in coming years, translating into an estimated free cash flow yield of about 18%.

The upgrade also reflects expectations that Adient could raise its fiscal 2026 guidance, which the UBS said may serve as an "immediate catalyst." Adient previously guided fiscal 2026 EBITDA to $845 million, but the forecast could rise to about $880 million as North American and Asian production outlooks improve, the report said.

As automakers shift production back to the US amid evolving trade policies, Adient is positioned as a potential "winner." The investment bank estimates the company could capture up to 300,000 incremental vehicle units, potentially adding $35 million in annual earnings.

Shares of the company were up more than 7% in recent Wednesday trading.

Price: 23.05, Change: +1.60, Percent Change: +7.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10